Cepralock vet.
Active substance
ATC code
Species
Cattle (dairy cows at drying off).
Indications
Prevention of new intramammary infections throughout the dry period.
In cows considered likely to be free of sub-clinical mastitis, the veterinary medicinal product can be used on its own in dry cow management and mastitis control.
Dose to be administered and administration route
Intramammary use.
The veterinary medicinal product has a dual tip nozzle. The cap of the syringe can be partially or fully removed. It is recommended to pinch the teat at the teat base as it aids in positioning the paste in the teat cistern, sealing the teat canal from the top.
Short tip option: The short tip option allows for a partial insertion technique so that the syringe only needs to be inserted in the teat end.
Long tip option: The long tip option may be used for treatment convenience for example to prevent the tip from flipping out due to a moving or nervous cow.
|
Step 1: Removal of the breakable cap |
Step 2: Long or short tip insertion |
Infuse the content of one syringe of the veterinary medicinal product into each udder quarter immediately after the last milking of the lactation (at drying off). Do not massage the teat or udder after infusion of the veterinary medicinal product because it is important that the sealant stays in the teat itself and does not enter the udder.
Care must be taken not to introduce pathogens into the teat in order to reduce the risk of post-infusion mastitis.
It is essential that the teat is thoroughly cleaned with the alcoholic disinfectant wipes provided. The teats should be wiped until there is no visible dirt collected on the wipe. Teats should be allowed to dry prior to infusion. Infuse aseptically and take care to avoid contamination of the syringe nozzle. Following infusion, it is advisable to use an appropriate teat dip or spray.
Under cold conditions the veterinary medicinal product may be warmed to room temperature in a warm environment, to aid syringeability.
Adverse reactions
None known.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
